Malignancy in giant cell tumor of bone

disease

On this page

Also known as bone giant cell sarcomaDedifferentiated giant cell tumorDedifferentiated giant cell tumourgiant cell bone sarcomagiant cell sarcoma of bonegiant cell sarcoma of the bonegiant cell tumor of bone, malignantgiant cell tumor of bone, malignant (morphologic abnormality)giant cell tumour of bone, malignantgiant cell tumour of bone, malignant (morphologic abnormality)malignancy in giant cell tumor of the bonemalignancy in giant cell tumour of the bonemalignant giant cell tumor of bonemalignant giant cell tumour of boneOSTEOCLASTOMA, malignant

Summary

Malignancy in giant cell tumor of bone (MONDO:0006287) is a cancer and 1 clinical trial. Top therapeutic interventions include fludarabine phosphate and lifileucel. A subtype of malignant giant cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	malignancy in giant cell tumor of bone
Mondo ID	MONDO:0006287
EFO	EFO:1000347
DOID	DOID:4719
NCIT	C4304
UMLS	C0334552
MedGen	87263
GARD	0024361
Is cancer (heuristic)	yes

Also known as: bone giant cell sarcoma · Dedifferentiated giant cell tumor · Dedifferentiated giant cell tumour · giant cell bone sarcoma · giant cell sarcoma of bone · giant cell sarcoma of the bone · giant cell tumor of bone, malignant · giant cell tumor of bone, malignant (morphologic abnormality) · giant cell tumour of bone, malignant · giant cell tumour of bone, malignant (morphologic abnormality) · malignancy in giant cell tumor of bone · malignancy in giant cell tumor of the bone · malignancy in giant cell tumour of the bone · malignant giant cell tumor of bone · malignant giant cell tumour of bone · OSTEOCLASTOMA, malignant

Data availability: 20 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › giant cell tumor › malignant giant cell tumor › malignancy in giant cell tumor of bone

Related subtypes (3): malignant tenosynovial giant cell tumor, malignant giant cell tumor of soft parts, giant cell tumor of soft tissue

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03449108	PHASE2	ACTIVE_NOT_RECRUITING	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUDARABINE PHOSPHATE	4	1
LIFILEUCEL	4	1

Drugs: Fludarabine Phosphate, Lifileucel